title: [Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].
abstract: Primary central nervous system lymphoma (PCNSL) is sensitive to both chemotherapy and radiation, but the blood-brain barrier limits the usefulness of the most effective chemotherapeutic agents. On the other hand radiation therapy carries along serious long term adverse events. In BBBD-therapy the blood-brain barrier is opened with intra-arterial mannitol infusion thus permitting both the chemotherapeutics and antibodies to enter through blood-brain barrier. So far 17 patients have started the therapy in our clinics. Ten patients have reached a complete response and 8 of these responses are ongoing with follow-up times of 6-62 months.
authors.affiliation: OYS, syöpätautien ja sädehoidon klinikka.
authors.forename: Outi
authors.initials: O
authors.lastname: Kuittinen
authors.forename: Topi
authors.initials: T
authors.lastname: Siniluoto
authors.forename: Matti
authors.initials: M
authors.lastname: Isokangas
authors.forename: Taina
authors.initials: T
authors.lastname: Turpeenniemi-Hujanen
authors.forename: Jenni
authors.initials: J
authors.lastname: Peltonen
authors.forename: Seppo
authors.initials: S
authors.lastname: Alahuhta
authors.forename: Eila
authors.initials: E
authors.lastname: Sonkajärvi
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008353:Mannitol / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D008353:Mannitol